Alkermes announces orphan drug designations for alixorexton in US for IH and EU for narcolepsy

Alkermes plc.

FDA grants orphan drug designation to alixorexton for idiopathic hypersomnia.
European Commission grants orphan drug designation to alixorexton for narcolepsy.
Alixorexton is an oral OX2R agonist in phase 3 for narcolepsy and phase 2 for IH.
ODD provides market exclusivity (7 yrs US, 10 yrs EU) if approved.
Alixorexton previously received FDA Breakthrough Therapy for NT1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.